The Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) will seek to determine if CEM provides more accurate cancer detection compared with digital breast tomosynthesis (DBT), as well as reduce false-positive exams in women with dense breasts, according to the ACR.

CEM combines mammography and vascular-based screening methods to highlight areas of unusual blood flow patterns that may indicate malignancy. Early studies of CEM in screening women with dense breasts have shown the potential benefit of CEM in the detection of breast cancer, the ACR noted.

The planned study will be managed by ACR's Center for Research and Innovation, with support from the Breast Cancer Research Foundation and GE. Dr. Christopher Comstock of Memorial Sloan Kettering Cancer Center will serve as the principal investigator.